Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype

Diffuse large B-cell lymphoma (DLBCL) accounts for 40% of non-Hodgkin lymphoma, and 30% to 40% of patients will succumb to relapsed/refractory disease (rrDLBCL). Patients with rrDLBCL generally have low long-term survival rates due to a lack of efficient salvage therapies. Small-molecule inhibitors...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Molecular cancer therapeutics 2022-04, Vol.21 (4), p.511-521
Hauptverfasser:	Preston, Samuel E J, Emond, Audrey, Pettersson, Filippa, Dupéré-Richer, Daphné, Abraham, Madelyn Jean, Riva, Alberto, Kinal, Mena, Rys, Ryan N, Johnson, Nathalie A, Mann, Koren K, Del Rincón, Sonia V, Licht, Jonathan D, Miller, Wilson H
Format:	Artikel
Sprache:	eng
Schlagworte:	Cell Line, Tumor Drug Resistance, Neoplasm Enhancer of Zeste Homolog 2 Protein - antagonists & inhibitors Humans Indazoles - pharmacology Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - genetics Lymphoma, Large B-Cell, Diffuse - metabolism Phenotype Pyridones - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!